<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293955</url>
  </required_header>
  <id_info>
    <org_study_id>Joins_Carp_IV_2009</org_study_id>
    <nct_id>NCT01293955</nct_id>
  </id_info>
  <brief_title>Assessment of Protective Effect of JOINS on Cartilage in Knee Osteoarthritis</brief_title>
  <acronym>Joins_Carp_Ⅳ</acronym>
  <official_title>A Randomized, Double Blinded, Parallel Group, Placebo-controlled Clinical Trial to Assess the Protective Effect of JOINS on Cartilage in Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  A Pilot study&#xD;
&#xD;
        -  Randomized and Double-blinded&#xD;
&#xD;
        -  Placebo controlled&#xD;
&#xD;
        -  In 2 parallel group (JOINS 200mg:Placebo = 1:1)&#xD;
&#xD;
        -  Overall 24 months treatment (JOINS:Placebo comparison up to 12 months, Additional&#xD;
           follow-up assessment up to 24 months)&#xD;
&#xD;
        -  Provide rescue medicine throughout whole clinical trial period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Assessment of Efficacy&#xD;
&#xD;
             1. Knee MRI(Magnetic resonance imaging):&#xD;
&#xD;
                  -  Assessment of cartilage volume, thickness in target knee&#xD;
&#xD;
                  -  GAG(glycosaminoglycan) concentration of target knee&#xD;
&#xD;
                  -  Assessment of Whole-Organ Magnetic Resonance Imaging Score (WORMS) of target&#xD;
                     knee&#xD;
&#xD;
             2. Knee radiography:&#xD;
&#xD;
                  -  Assessment of changes in minimal medial JSW(Joint Space Width) of target knee.&#xD;
&#xD;
             3. Knee pain(VAS)&#xD;
&#xD;
                  -  Assessment changes of pain in target knee.&#xD;
&#xD;
             4. K-WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index for Korean)&#xD;
&#xD;
                  -  Assessment score change for pain(5 questions), stiffness(2 questions) and&#xD;
                     physical function(17 questions).&#xD;
&#xD;
                  -  The questionnaire is self-administered by the patients.&#xD;
&#xD;
             5. Used frequency of rescue medicine.&#xD;
&#xD;
             6. Biochemical cartilage and bone markers&#xD;
&#xD;
                  -  Blood and urine sample will be collected all through the morning after a night&#xD;
                     fasting period since 10 pm the previous day to avoid the variations.&#xD;
&#xD;
        2. Assessment of Safety&#xD;
&#xD;
             1. Adverse event&#xD;
&#xD;
             2. Laboratory assessment&#xD;
&#xD;
             3. Vital sign&#xD;
&#xD;
             4. 12-lead ECG&#xD;
&#xD;
             5. Physical examination&#xD;
&#xD;
        3. Enrollment: 76&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee MRI</measure>
    <time_frame>up to 4 times</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee radiography</measure>
    <time_frame>up to 4 times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee pain(VAS)</measure>
    <time_frame>up to 6 times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K-WOMAC</measure>
    <time_frame>up to 6 times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of rescue medication</measure>
    <time_frame>up to 6 times</time_frame>
    <description>The quantity of rescue medicine will be counted by investigator and recorded in official clinical research document form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>up to 6 times</time_frame>
    <description>Patients will need to be strictly fasting from the night before the visit. The data of biological cartilage and bone markers will be collected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>JOINS 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of JOINS 200mg is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with JOINS 200mg for another 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet of Placebo is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with Placebo for another 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JOINS 200mg</intervention_name>
    <description>1 tablet at each time, 3 times a day</description>
    <arm_group_label>JOINS 200mg</arm_group_label>
    <other_name>JOINS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo of Joins 200mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A female is eligible if she is of:&#xD;
&#xD;
               -  Non-child bearing potential (i.e., physiologically incapable of becoming&#xD;
                  pregnant), including any female who is at least 2 year after post- menopausal&#xD;
&#xD;
               -  Child bearing potential and agrees to the acceptable contraceptive methods used&#xD;
                  consistently and correctly&#xD;
&#xD;
               -  Pregnancy test result of negative at screening&#xD;
&#xD;
          2. Primary Knee OA(Osteoarthritis) on medial femorotibial compartment based on&#xD;
             ACR(American College Rheumatology) Criteria.&#xD;
&#xD;
               -  ACR Criteria : With Knee pain and satisfied at least 1 of 3 (① age &gt; 50 years,&#xD;
                  morning stiffness &lt; 30 minute, ③ Presence of Crepitus and Osteophytes on motion)&#xD;
&#xD;
          3. Appropriately signed and dated informed consent has been obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Rheumatoid arthritis or inflammatory arthritis.&#xD;
&#xD;
          2. Bilateral total knee replacement already treated, or planning for the procedure.&#xD;
&#xD;
          3. Knee prosthesis already implanted, or foreseen within the next year.&#xD;
&#xD;
          4. Clinically significant hip osteoarthritis.&#xD;
&#xD;
          5. Severe renal insufficiency defined as creatinine clearance &lt; 30ml/mln(Cockcroft&#xD;
             formula).&#xD;
&#xD;
          6. Clinically significant pulmonary, hepatic, renal or heart disorder or diagnosis&#xD;
             crucial disease by investigator ( Glycosuria(Diabetes mellitus) or asthma patients are&#xD;
             excluded from this clinical study and the patients who has a clinically significant&#xD;
             disease are also excluded.).&#xD;
&#xD;
          7. MRI contraindications : overweight, inferior limb diameter non-fitting the knee&#xD;
             antenna, inserted pace-maker, metallic prosthesis( if known to interfere with MRI&#xD;
             procedure or if known to be unsafe for MRI), metallic clips, insulin pump, cytostatic&#xD;
             pump, hearing aid, essential tremor, claustrophobia, etc,.&#xD;
&#xD;
          8. Allergic reaction to Clinical trial medication.&#xD;
&#xD;
          9. Other clinical trial drugs during the 1 month prior to the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myoungchul Lee, PH.D..</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopedics, Seoul National University hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cartilage</keyword>
  <keyword>knee osteoarthritis</keyword>
  <keyword>protective effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

